Investigational drug · Phase 2
MK-4830
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Esophageal Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
10
3 still active
All registered trials
13
Any phase or sponsor naming "MK-4830"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-4830", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
- Esophageal Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
- Carcinoma, Renal Cell
- Colorectal Cancer
- Small Cell Lung Cancer
- Melanoma
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Melanoma · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-4830" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03564691 · 470 participants · Start Jul 11, 2018 · Primary completion Sep 26, 2025
Drug: MK-4830; Pembrolizumab and 6 more · For: Neoplasms
Sites: San Francisco, California; Detroit, Michigan; St Louis, Missouri · 37 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165070 · 450 participants (planned) · Start Dec 19, 2019 · Primary completion Feb 13, 2032
Drug: Pembrolizumab; Carboplatin and 8 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 47 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04895722 · 302 participants · Start Jun 25, 2021 · Primary completion May 21, 2025
Drug: Pembrolizumab; Pembrolizumab/Quavonlimab and 3 more · For: Colorectal Cancer
Sites: Orange City, Florida; Athens, Georgia; Chicago, Illinois · 109 sites in all
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626518 · 263 participants · Start Dec 17, 2020 · Primary completion Jul 23, 2026
Drug: Pembrolizumab; MK-4830 and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05319730 · 230 participants (planned) · Start May 16, 2023 · Primary completion Jun 11, 2027
Drug: Paclitaxel; Irinotecan and 10 more · For: Esophageal Squamous Cell Carcinoma
Sites: Tucson, Arizona; Los Angeles, California; East Syracuse, New York · 58 sites in all
- Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05446870 · 160 participants · Start Jul 25, 2022 · Primary completion Dec 20, 2023
Drug: Pembrolizumab; Paclitaxel and 4 more · For: High-grade Serous Ovarian Carcinoma; Ovarian Carcinoma
Sites: Aurora, Colorado; Jacksonville, Florida; Miami, Florida · 45 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04303169 · 146 participants · Start Jun 26, 2020 · Primary completion Sep 24, 2025
Drug: Pembrolizumab; Vibostolimab and 4 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 29 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165096 · 128 participants · Start Jan 21, 2020 · Primary completion Apr 30, 2025
Drug: Pembrolizumab; Boserolimab and 4 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 39 sites in all
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04924101 · 122 participants · Start Jul 15, 2021 · Primary completion Jun 23, 2025
Drug: Pembrolizumab; MK-4830 and 5 more · For: Small Cell Lung Cancer
Sites: Gilbert, Arizona; Aurora, Colorado; Atlanta, Georgia · 49 sites in all
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04938817 · 110 participants (planned) · Start Aug 19, 2021 · Primary completion Dec 10, 2029
Drug: coformulation pembrolizumab/quavonlimab; lenvatinib and 3 more · For: Small Cell Lung Carcinoma
Sites: Gilbert, Arizona; Atlanta, Georgia; Fort Wayne, Indiana · 48 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient.
Kachlik Z, Bażewicz I, Ciarka A, et al. · Front Pharmacol 2024
- KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
André T, Pietrantonio F, Avallone A, et al. · Future Oncol 2023
- A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.
Gresham LM, Kirchhof MG · SAGE Open Med Case Rep 2023
- Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, et al. · Clin Cancer Res 2022
- Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, et al. · Clin Cancer Res 2022
- First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, et al. · Clin Cancer Res 2022
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.